In-network processing of the GPU-based real-time DXT compression

N. Kim,Jae-Yong Yoo,N. Kim,JongWon Kim

DOI: https://doi.org/10.1145/2079327.2079351

2011-12-06

Abstract:In this paper, we show our on-going work on realizing a PC-based network switch that provides low-latency in-network processing of GPU-based DXT compression.

What problem does this paper attempt to address?

Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity

Zhaohui Cai,Raj Kalkeri,Mi Wang,Benjamin Haner,Dominic Dent,Bahar Osman,Paul Skonieczny,Jeremy Ross,Sheau-Line Feng,Rongman Cai,Mingzhu Zhu,Shane Cloney-Clark,Joyce S. Plested

DOI: https://doi.org/10.3390/microorganisms12061201

IF: 4.5

2024-06-14

Microorganisms

Abstract:The evaluation of coronavirus disease 2019 (COVID-19) vaccine immunogenicity remains essential as the severe acute respiratory syncytial virus 2 (SARS-CoV-2) pandemic continues to evolve and as additional variants emerge. Neutralizing antibodies are a known correlate of protection for SARS-CoV-2 vaccines. A pseudovirus neutralization (PNT) assay was developed and validated at Novavax Clinical Immunology Laboratories to allow for the detection of neutralizing antibodies in vaccine clinical trial sera. The PNT assay was precise, accurate, linear, and specific in measuring SARS-CoV-2 neutralization titers in human serum for ancestral strain and the Omicron subvariants BA.5 and XBB.1.5, with an overall geometric coefficient of variation of ≤43.4%, a percent relative bias within the expected range of −60% to 150%, and a linearity value of R2 > 0.98 for all three strains. This pseudovirus assay will be useful for the analysis of vaccine clinical trial samples to assess vaccine immunogenicity. Future work will focus on modifying the assay for emerging variants, including XBB.1.16, EG.5.1, BA.2.86, and any other variants that emerge in the ongoing pandemic.

microbiology
Rapid Gel Card Agglutination Assays for Serological Analysis Following SARS-CoV-2 Infection in Humans

Diana Alves,Rodrigo Curvello,Edward Henderson,Vidhishri Kesarwani,Julia A. Walker,Samuel C. Leguizamon,Heather McLiesh,Vikram Singh Raghuwanshi,Hajar Samadian,Erica M. Wood,Zoe K. McQuilten,Maryza Graham,Megan Wieringa,Tony M. Korman,Timothy F. Scott,Mark M. Banaszak Holl,Gil Garnier,Simon R. Corrie

DOI: https://doi.org/10.1021/acssensors.0c01050

IF: 8.9

2020-07-16

ACS Sensors

Abstract:High-throughput and rapid serology assays to detect the antibody response specific to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in human blood samples are urgently required to improve our understanding of the effects of COVID-19 across the world. Short-term applications include rapid case identification and contact tracing to limit viral spread, while population screening to determine the extent of viral infection across communities is a longer-term need. Assays developed to address these needs should match the ASSURED criteria. We have identified agglutination tests based on the commonly employed blood typing methods as a viable option. These blood typing tests are employed in hospitals worldwide, are high-throughput, fast (10–30 min), and automated in most cases. Herein, we describe the application of agglutination assays to SARS-CoV-2 serology testing by combining column agglutination testing with peptide–antibody bioconjugates, which facilitate red cell cross-linking only in the presence of plasma containing antibodies against SARS-CoV-2. This simple, rapid, and easily scalable approach has immediate application in SARS-CoV-2 serological testing and is a useful platform for assay development beyond the COVID-19 pandemic.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acssensors.0c01050?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acssensors.0c01050</a>.LC/MS analysis of synthesized peptides (Figure S1); SDS-PAGE gel for anti-D-IgG purification (Figure S2); optical microscopy images distinguishing true/false-positive gel card results (Figure S3); and list of clinical samples used in the study (Table S1) (<a class="ext-link" href="/doi/suppl/10.1021/acssensors.0c01050/suppl_file/se0c01050_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

chemistry, multidisciplinary, analytical,nanoscience & nanotechnology
A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection

Mingzhu Zhu,Shane Cloney-Clark,Sheau-Line Feng,Anand Parekh,Drew Gorinson,David Silva,Paul Skonieczny,Adjele Wilson,Raj Kalkeri,Wayne Woo,Miranda R Cai,Louis Fries,Greg Glenn,Joyce S Plested

DOI: https://doi.org/10.3390/microorganisms11071789

IF: 4.5

2023-07-11

Microorganisms

Abstract:As the COVID-19 pandemic continues, variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge. Immunogenicity evaluation of vaccines and identification of correlates of protection for vaccine effectiveness is critical to aid the development of vaccines against emerging variants. Anti-recombinant spike (rS) protein immunoglobulin G (IgG) quantitation in the systemic circulation (serum/plasma) is shown to correlate with vaccine efficacy. Thus, an enzyme-linked immunosorbent assay (ELISA)-based binding assay to detect SARS-CoV-2 (ancestral and variant strains) anti-rS IgG in human serum samples was developed and validated. This assay successfully met acceptance criteria for inter/intra-assay precision, specificity, selectivity, linearity, lower/upper limits of quantitation, matrix effects, and assay robustness. The analyte in serum was stable for up to 8 freeze/thaw cycles and 2 years in -80 °C storage. Similar results were observed for the Beta, Delta, and Omicron BA.1/BA.5/XBB.1.5 variant-adapted assays. Anti-rS IgG assay results correlated significantly with neutralization and receptor binding inhibition assays. In addition, usage of international reference standards allows data extrapolation to WHO international units (BAU/mL), facilitating comparison of results with other IgG assays. This anti-rS IgG assay is a robust, high-throughput method to evaluate binding IgG responses to S protein in serum, enabling rapid development of effective vaccines against emerging COVID-19 variants.
Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen

Ryo Kobayashi,Ryosei Murai,Koichi Asanuma,Yoshihiro Fujiya,Satoshi Takahashi

DOI: https://doi.org/10.1016/j.jiac.2021.01.007

IF: 2.065

2021-06-01

Journal of Infection and Chemotherapy

Abstract:IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is rapidly spreading all over the world. A new quantifying reagent for detecting SARS-CoV-2 antigen was developed for early and accurate detection. We evaluated the novel quantitative reagent for detecting SARS-CoV-2 antigen using an automated laboratory device.MethodsOne-hundred nasopharyngeal samples were collected from 47 SARS-CoV-2-infected patients, and 200 samples were collected from healthy donners. We measured the SARS-CoV-2 antigen and nucleic acid using Lumipulse Presto SARS-CoV-2 Ag and the 2019 Novel Coronavirus Detection Kit, respectively.ResultsThe sensitivity and specificity of the SARS-CoV-2 antigen test were 75.7% (56/74) and 96.0% (192/200), respectively. The concordance rate in the positive group between the antigen and nucleic acid tests was 66% (66/100). In addition, the correlation coefficient between the concentration of SARS-CoV-2 antigen and the level of SARS-CoV-2 RNA was 0.74. There were 19 discrepant samples in which SARS-CoV-2 RNA was detected without SARS-CoV-2 antigen. There was significant difference between the discrepant and matched samples in terms of the time since symptom onset: the 19 discrepant samples were collected a median of 33 days after onset, while the 55 matched samples were collected a median of 19 days after onset. In addition, the 19 discrepant samples were collected from patients who were immune against SARS-CoV-2.ConclusionsThis novel SARS-CoV-2 antigen detection assay is highly sensitive, rapid, accurate, easily diagnostic. It may be useful in both clinical diagnosis and in screening because it does not require special methods such as PCR.

pharmacology & pharmacy,infectious diseases
A Reliable Indirect ELISA Protocol for Detection of Human Antibodies Directed to SARS-CoV-2 NP Protein

Arwa A. Faizo,Thamir A. Alandijany,Ayman T. Abbas,Sayed S. Sohrab,Sherif A. El-Kafrawy,Ahmed M. Tolah,Ahmed M. Hassan,Esam I. Azhar

DOI: https://doi.org/10.3390/diagnostics11050825

IF: 3.6

2021-05-02

Diagnostics

Abstract:A few months ago, the availability of a reliable and cost-effective testing capacity for COVID-19 was a concern for many countries. With the emergence and circulation of new SARS-CoV-2 variants, another layer of challenge can be added for COVID-19 testing at both molecular and serological levels. This is particularly important for the available tests principally designed to target the S gene/protein where multiple mutations have been reported. Herein, the SARS-CoV-2 NP recombinant protein was utilized to develop a simple and reliable COVID-19 NP human IgG ELISA. The optimized protocol was validated against a micro-neutralization (MN) assay, in-house S-based ELISA, and commercial chemiluminescence immunoassay (CLIA). The developed assay provides 100% sensitivity, 98.9% specificity, 98.9% agreement, and high overall accuracy with an area under curve equal to 0.9998 ± 0.0002 with a 95% confidence interval of 0.99 to 1.00. The optical density values of positive samples significantly correlated with their corresponding MN titers. The assay specifically detects IgG antibodies to the SARS-CoV-2 NP protein and does not cross-detect IgG to the viral S protein. Moreover, it does not cross-react with antibodies related to other coronaviruses (e.g., the Middle East respiratory syndrome coronavirus or human coronavirus HKU1). The availability of this reliable COVID-19 NP IgG ELISA protocol is highly valuable for its diagnostic and epidemiological applications.
An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization

Nicholas Wohlgemuth,Kendall Whitt,Sean Cherry,Ericka Kirkpatrick Roubidoux,Chun-Yang Lin,Kim J. Allison,Ashleigh Gowen,Pamela Freiden,E. Kaitlynn Allen,,Aditya H. Gaur,Jeremie H. Estepp,Li Tang,Tomi Mori,Diego R. Hijano,Hana Hakim,Maureen A. McGargill,Florian Krammer,Michael A. Whitt,Joshua Wolf,Paul G. Thomas,Stacey Schultz-Cherry,St. Jude Investigative Team,

DOI: https://doi.org/10.1128/spectrum.01059-21

IF: 3.7

2021-10-28

Microbiology Spectrum

Abstract:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and has since caused a global pandemic resulting in millions of cases and deaths. Diagnostic tools and serological assays are critical for controlling the outbreak, especially assays designed to quantitate neutralizing antibody levels, considered the best correlate of protection. As vaccines become increasingly available, it is important to identify reliable methods for measuring neutralizing antibody responses that correlate with authentic virus neutralization but can be performed outside biosafety level 3 (BSL3) laboratories. While many neutralizing assays using pseudotyped virus have been developed, there have been few studies comparing the different assays to each other as surrogates for authentic virus neutralization. Here, we characterized three enzyme-linked immunosorbent assays (ELISAs) and three pseudotyped vesicular stomatitis virus (VSV) neutralization assays and assessed their concordance with authentic virus neutralization. The most accurate assays for predicting authentic virus neutralization were luciferase- and secreted embryonic alkaline phosphatase (SEAP)-expressing pseudotyped virus neutralizations, followed by green fluorescent protein (GFP)-expressing pseudotyped virus neutralization, and then the ELISAs. IMPORTANCE The ongoing COVID-19 pandemic is caused by infection with severe acute respiratory syndrome virus 2 (SARS-CoV-2). Prior infection or vaccination can be detected by the presence of antibodies in the blood. Antibodies in the blood are also considered to be protective against future infections from the same virus. The "gold standard" assay for detecting protective antibodies against SARS-CoV-2 is neutralization of authentic SARS-CoV-2 virus. However, this assay can only be performed under highly restrictive biocontainment conditions. We therefore characterized six antibody-detecting assays for their correlation with authentic virus neutralization. The significance of our research is in outlining the advantages and disadvantages of the different assays and identifying the optimal surrogate assay for authentic virus neutralization. This will allow for more accurate assessments of protective immunity against SARS-CoV-2 following infection and vaccination.

microbiology
Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2

Ji Youn Lim,Alyssa Fiore,Bruce Le,Corinne Minzer,Halle White,Krystle Burinski,Humaira Janwari,David Wright,Sasha Perebikovsky,Ralph Davis,David Okrongly,Aravind Srinivasan

DOI: https://doi.org/10.1101/2024.07.24.24310905

2024-07-26

Abstract:Neutralizing antibody titer elicited through infection or vaccination is accepted as a reliable surrogate for protection from SARS-CoV-2 infection, hospitalization, and mortality. The gold standard for measuring neutralizing antibody levels relies on culturing live virus in the presence of a target cell and quantitating the level where 50% of the target cells are infected. These assays have numerous technical challenges, not the least is the requirement for a BSL-3 laboratory to perform the live virus testing. We developed the Q-NAb IgG Test for the quantitative determination of neutralizing antibodies against SARS-CoV-2 variants, traceable to WHO International Standards. The test utilizes a novel Fusion Protein that mimics the Spike receptor binding domain docked to the human ACE2 protein and effectively blocks non-neutralizing antibodies in the sample. After pre-blocking sequesters the non-neutralizing antibodies from the samples, direct binding of the residual neutralizing antibodies to variant RBDs coated in the wells of the microtiter plate is measured with a fluorescent secondary antibody. Results of the Q-NAb IgG Test agree with a live virus Microneutralization Assay for both the Ancestral strain (WA1-2020) and the Omicron BA.5 (COR-22-063113/2022) variant (Spearmans correlation, ρ = 0.87 and 0.92, respectively). The analytical performance (LoB, LoD, LoQ, linearity, precision, and interference) of the Q-NAb IgG Test was established along with sensitivity and specificity using a panel of monoclonal neutralizing and non-neutralizing anti-SARS-CoV-2 antibodies. Clinical sensitivity and specificity using pre-pandemic, convalescent, and vaccinated serum and plasma samples is also reported. The advantages of the Q-NAb IgG Test are its strong correlation to live virus neutralization tests, traceability to WHO International Standards, convenient microtiter plate format, low sample volume requirements, and suitability for a BSL-2 laboratory.

Infectious Diseases (except HIV/AIDS)
D313Y mutation in the differential diagnosis of white matter lesions: Experiences from a multiple sclerosis outpatient clinic

Jana Becker,A. Rolfs,N. Karabul,P. Berlit,M. Kraemer

DOI: https://doi.org/10.1177/1352458516638747

2016-03-18

Multiple Sclerosis

Abstract:White matter lesions (WML) in younger patients might be due to a variety of neurological disorders. Fabry disease (FD), an x-linked inherited lysosomal storage disorder, happens to be misdiagnosed as multiple sclerosis (MS). In two middle-aged female patients, presenting bilateral WML, diagnosis of MS turned out to be doubtful. Human genetic analysis presented the Fabry mutation D313Y, in which clinical impact is still unclear. Disease manifestations outside the central nervous system were not detected. Our findings support the suspicion that Fabry mutation D313Y may be involved in neural damage resulting in WML.
Development of a unit conversion tool for five quantitative anti-spike assays and agreement analysis of three qualitative anti-nucleocapsid assays for SARS-CoV-2

Serge Ouoba,Aya Sugiyama,Ko Ko,Ulugbek Khudayberdievich Mirzaev,Kanon Abe,Bunthen E,Zayar Phyo,Kobiljon Khusniddin Khalilov,Akemi Kurisu,Tomoyuki Akita,Kazuaki Takahashi,Hiroshi Sasaki,Takumi Yamamoto,Junko Tanaka

DOI: https://doi.org/10.1002/jmv.29826

Abstract:Commercially available assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike (S) or anti-nucleocapsid (N) antibodies differ in units, making results comparisons challenging. This study aimed to develop conversion equations between five quantitative anti-S antibody tests and to assess the agreement over time between three qualitative anti-N antibody tests. Blood samples from 24 216 vaccinated healthcare workers in Hiroshima Prefecture, Japan, were analyzed for anti-S antibodies using five quantitative tests (Abbott, Fujirebio, Ortho, Sysmex, Roche) and for anti-N antibodies using three qualitative tests (Abbott, Sysmex, Roche). Geometric mean regression was performed to establish equations for converting measured values between the five quantitative tests. Fleiss κ statistic was used to assess the agreement between the three qualitative tests. A strong correlation (Pearson's coefficient r > 0.9) was found for each pair of the five quantitative tests measuring anti-S antibodies, enabling the development of equations to convert values between each pair. Using these equations, which are based on the original output unit of each test, values obtained from one test can be transformed to be equivalent to the corresponding values in another test. For the three tests for anti-N antibodies, the agreement was substantial in the total sample (Fleiss' κ, 0.74) and moderate among those with self-reported past coronavirus disease 2019 (COVID-19) infection (Fleiss' κ, 0.39). The agreement decreased with time after infection. Reduced agreement between anti-N antibodies tests over time suggests caution in comparing seroepidemiological studies of COVID-19 exposure based on anti-N antibodies measurement. The findings could help improve antibody measurement systems and inform public health decision-makers.
Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination

Toshihiro Takahashi,Tomohiko Ai,Kaori Saito,Shuko Nojiri,Maika Takahashi,Gene Igawa,Takamasa Yamamoto,Abdullah Khasawneh,Faith Jessica Paran,Satomi Takei,Yuki Horiuchi,Takayuki Kanno,Minoru Tobiume,Makoto Hiki,Mitsuru Wakita,Takashi Miida,Atsushi Okuzawa,Tadaki Suzuki,Kazuhisa Takahashi,Toshio Naito,Yoko Tabe

DOI: https://doi.org/10.1371/journal.pone.0291670

IF: 3.7

2023-09-20

PLoS ONE

Abstract:The COVID-19 antibody test was developed to investigate the humoral immune response to SARS-CoV-2 infection. In this study, we examined whether S antibody titers measured using the anti-SARS-CoV-2 IgG II Quant assay (S-IgG), a high-throughput test method, reflects the neutralizing capacity acquired after SARS-CoV-2 infection or vaccination. To assess the antibody dynamics and neutralizing potency, we utilized a total of 457 serum samples from 253 individuals: 325 samples from 128 COVID-19 patients including 136 samples from 29 severe/critical cases (Group S), 155 samples from 71 mild/moderate cases (Group M), and 132 samples from 132 health care workers (HCWs) who have received 2 doses of the BNT162b2 vaccinations. The authentic virus neutralization assay, the surrogate virus neutralizing antibody test (sVNT), and the Anti-N SARS-CoV-2 IgG assay (N-IgG) have been performed along with the S-IgG. The S-IgG correlated well with the neutralizing activity detected by the authentic virus neutralization assay (0.8904. of Spearman's rho value, p < 0.0001) and sVNT (0.9206. of Spearman's rho value, p < 0.0001). However, 4 samples (2.3%) of S-IgG and 8 samples (4.5%) of sVNT were inconsistent with negative results for neutralizing activity of the authentic virus neutralization assay. The kinetics of the SARS-CoV-2 neutralizing antibodies and anti-S IgG in severe cases were faster than the mild cases. All the HCWs elicited anti-S IgG titer after the second vaccination. However, the HCWs with history of COVID-19 or positive N-IgG elicited higher anti-S IgG titers than those who did not have it previously. Furthermore, it is difficult to predict the risk of breakthrough infection from anti-S IgG or sVNT antibody titers in HCWs after the second vaccination. Our data shows that the use of anti-S IgG titers as direct quantitative markers of neutralizing capacity is limited. Thus, antibody tests should be carefully interpreted when used as serological markers for diagnosis, treatment, and prophylaxis of COVID-19.

multidisciplinary sciences
Pre-clinical and clinical evaluation of a surface plasmon field-enhanced fluorescence spectroscopy (SPFS) antigen test for detecting SARS-CoV-2

Nobuyuki Ashizawa,Takahiro Takazono,Kenji Ota,Yuya Ito,Tatsuro Hirayama,Kazuaki Takeda,Shotaro Ide,Naoki Iwanaga,Ayumi Fujita,Masato Tashiro,Naoki Hosogaya,Norihiko Akamatsu,Kosuke Kosai,Takeshi Tanaka,Hironori Kobayashi,Ryosuke Yamauchi,Chie Segawa,Hikaru Koizumi,Natsumi Taka,Haretsugu Hishigaki,Kazuko Yamamoto,Koichi Izumikawa,Katsunori Yanagihara,Hiroshi Mukae

DOI: https://doi.org/10.1016/j.jiac.2024.08.019

2024-08-27

Abstract:Introduction: The diagnostic tools of nucleic acid amplification tests and antigen tests have been extensively employed for the detection of Coronavirus disease 2019 (COVID-19). Although the reverse-transcriptase polymerase chain reaction (RT)-PCR test has high sensitivity and specificity, it is a time-consuming and labor-intensive process. On the other hand, antigen tests are simple and prompt, however, their low sensitivity and potential for false positives have been identified as limitations. In light of these factors, the development of novel tests that combine speed and clinical dependability is a promising prospect. Methods: Surface plasmon field-enhanced fluorescence spectroscopy (SPFS) excites chromophores by means of an enhanced electromagnetic field induced on a gold film surface. It enables the highly sensitive measurement of biomarkers in a short and simple 20-min window. In this study, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) SPFS-based antigen test targeting the SARS-CoV-2 nucleocapsid protein was performed and evaluated in 25 patients with COVID-19 and 10 non-infected controls. Results: A positive correlation was observed between antigen levels determined by SPFS and RNA levels determined via RT-PCR. The sensitivity values were 100 %, 92 %, and 62.5 %; and the specificity values were 100 %, 90 %, and 100 %; for nasopharyngeal swabs, nasal swabs, and saliva specimens when the cutoff values were set to 65.1, 0.2, and 1.5 pg/mL, respectively. No clinically problematic cross-reactivity with analogous coronaviruses was observed. Conclusions: The SARS-CoV-2 SPFS antigen test showed excellent clinical diagnostic accuracy for nasopharyngeal and nasal swabs, with a rapid turnaround.
Nanoparticle-Supported, Rapid, Digital Quantification of Neutralizing Antibodies Against SARS-CoV-2 Variants

Seyedsina Mirjalili,MD Ashif Ikbal,Ching-Wen Hou,Maziyar Kalatehmohammdi,Yeji Choi,LAIMONAS KELBAUSKAS,Laura A. VanBlargan,Brenda G. Hogude,Vel Murugan,Michael S. Diamond,Chao Wang

DOI: https://doi.org/10.1101/2024.11.05.622148

2024-11-06

Abstract:The measurement of neutralizing immune responses to viral infection is essential, given the heterogeneity of human immunity and the emergence of new virus strains. However, neutralizing antibody (nAb) assays often require high-level biosafety containment, sophisticated instrumentation, and long detection times. Here, as a proof-of-principle, we designed a nanoparticle-supported, rapid, electronic detection (NasRED) assay to assess the neutralizing potency of monoclonal antibodies (mAbs) against SARS-CoV-2. The gold nanoparticles (AuNPs) coated with human angiotensin-converting enzyme 2 (ACE2) protein as nAb potency reporters were mixed with the mAbs to be tested, as well as streptavidin-conjugated multivalent spike (S) protein or their receptor binding domains (RBD). High-affinity and ACE2-competitive nAbs alter the S (or RBD)-to-ACE2 binding level and modulate AuNP cluster formation and precipitation. The amount of free-floating AuNP reporters is quantified by a semiconductor-based readout system that measures the AuNPs' optical extinction, producing nAb signals that can differentiate SARS-CoV-2 variants (Wuhan-Hu-1, Gamma, and Omicron). The modular design nature, short assay time (less than 30 minutes), and portable and inexpensive readout system make this NasRED-nAb assay applicable to measuring vaccine potency, immune responses to infection, and the efficacy of antibody-based therapies.

Immunology
Immunomolecular assay based on selective virion capture by spike antibody and viral nucleic acid amplification for detecting intact SARS-CoV-2 particles

Xiaoli Wu,Junye Liu,Hongpeng Zhang,Hua Zhou,Wen Wang,Yuanyan Ma,Shimei Shen,Xuefei Cai,Ailong Huang,Deqiang Wang

DOI: https://doi.org/10.1186/s12951-022-01558-8

2022-09-05

Abstract:Background: Effective therapeutics and vaccines for coronavirus disease 2019 (COVID-19) are currently lacking because of the mutation and immune escape of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on the propagation characteristics of SARS-CoV-2, rapid and accurate detection of complete virions from clinical samples and the environment is critical for assessing infection risk and containing further COVID-19 outbreaks. However, currently applicable methods cannot achieve large-scale clinical application due to factors such as the high viral load, cumbersome virus isolation steps, demanding environmental conditions, and long experimental periods. In this study, we developed an immuno molecular detection method combining capture of the viral spike glycoprotein with monoclonal antibodies and nucleic acid amplification via quantitative reverse transcription PCR to rapidly and accurately detect complete virions. Results: After constructing a novel pseudovirus, screening for specific antibodies, and optimizing the detection parameters, the assay achieved a limit of detection of 9 × 102 transduction units/mL of viral titer with high confidence (~ 95%) and excellent stability against human serum and common virus/pseudovirus. The coefficients of variation were 1.0 ~ 2.0% for intra-assay and inter-assay analyses, respectively. Compared with reverse transcription-PCR, the immunomolecular method more accurately quantified complete virions. SARS-CoV-2/pseudovirus was more stable on plastic and paper compared with aluminum and copper in the detection of SARS-CoV-2 pseudovirus under different conditions. Complete virions were detected up to 96 h after they were applied to these surfaces (except for copper), although the titer of the virions was greatly reduced. Conclusion: Convenient, inexpensive, and accurate complete virus detection can be applied to many fields, including monitoring the infectivity of convalescent and post-discharge patients and assessing high-risk environments (isolation rooms, operating rooms, patient living environments, and cold chain logistics). This method can also be used to detect intact virions, including Hepatitis B and C viruses, human immunodeficiency virus, influenza, and the partial pulmonary virus, which may further improve the accuracy of diagnoses and facilitate individualized and precise treatments.
Novel enzyme-linked aptamer-antibody sandwich assay and hybrid lateral flow strip for SARS-CoV-2 detection

Shih-Wei Wu,Ying-Ju Chen,Yu-Wen Chang,Cheng-Yang Huang,Biing-Hui Liu,Feng-Yih Yu

DOI: https://doi.org/10.1186/s12951-023-02191-9

IF: 10.2

2024-01-03

Journal of Nanobiotechnology

Abstract:Abstract We have successfully generated oligonucleotide aptamers (Apts) and monoclonal antibodies (mAbs) targeting the recombinant nucleocapsid (N) protein of SARS-CoV-2. Apts were obtained through seven rounds of systematic evolution of ligands by exponential enrichment (SELEX), while mAbs were derived from the 6F6E11 hybridoma cell line. Leveraging these Apts and mAbs, we have successfully devised two innovative and remarkably sensitive detection techniques for the rapid identification of SARS-CoV-2 N protein in nasopharyngeal samples: the enzyme-linked aptamer-antibody sandwich assay (ELAAA) and the hybrid lateral flow strip (hybrid-LFS). ELAAA exhibited an impressive detection limit of 0.1 ng/mL, while hybrid-LFS offered a detection range of 0.1 – 0.5 ng/mL. In the evaluation using ten nasopharyngeal samples spiked with known N protein concentrations, ELAAA demonstrated an average recovery rate of 92%. Additionally, during the assessment of five nasopharyngeal samples from infected individuals and ten samples from healthy volunteers, hybrid-LFS displayed excellent sensitivity and specificity. Our study introduces a novel and efficient on-site approach for SARS-CoV-2 detection in nasopharyngeal samples. The reliable hybrid Apt-mAb strategy not only advances virus diagnostic methods but also holds promise in combating the spread of related diseases.

biotechnology & applied microbiology,nanoscience & nanotechnology
Clinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS‐CoV‐2 Omicron BA.1 and BA.5 variants

Beomki Lee,Jae‐Hoon Ko,Yong Chan Kim,Jin Yang Baek,Yoon Soo Park,Kyoung‐Ho Song,Eu Suk Kim,Kyoung Hwa Lee,Young Goo Song,Jin Young Ahn,Jun Yong Choi,Won Suk Choi,Seongman Bae,Sung‐Han Kim,Hye Won Jeong,Young Jae Lee,Hye‐Jin Kim,Ju‐Yeon Choi,Byoungguk Kim,Shin‐Woo Kim,Ki Tae Kwon,Kyong Ran Peck,Eun‐Suk Kang

DOI: https://doi.org/10.1002/jmv.29329

IF: 20.693

2023-12-25

Journal of Medical Virology

Abstract:Developing new antibody assays for emerging SARS‐CoV‐2 variants is challenging. SARS‐CoV‐2 surrogate virus neutralization tests (sVNT) targeting Omicron BA.1 and BA.5 have been devised, but their performance needs to be validated in comparison with quantitative immunoassays. First, using 1749 PRNT‐positive sera, we noticed that log‐transformed optical density (OD) ratio of wild‐type (WT) sVNT exhibited better titer‐correlation with plaque reduction neutralization test (PRNT) than % inhibition value. Second, we tried 798 dilutional titration tests with 103 sera, but nonlinear correlation between OD ratio and antibody concentration limited titration of sVNT. Third, the titer‐correlations of two sVNT kits for BA.1 and two quantitative immunoassays for WT were evaluated with BA.1 and BA.5 PRNT. All tested kits exhibited a linear correlation with PRNT titers, but the sVNT kits exhibited high false‐negative rates (cPass‐BA.1 kit, 45.4% for BA.1 and 44.2% for BA.5; STANDARD F‐BA.1 kit, 1.9% for BA.1 and 2.2% for BA.5), while quantitative immunoassays showed 100% sensitivity. Linear mixed‐effects model suggested superior titer‐correlation with PRNT for quantitative immunoassays compared to sVNT kits. Taken together, the use of quantitative immunoassays for WT, rather than rapid development of new kits, would be practical for predicting neutralizing activities against emerging new variants.

virology
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

Chee Wah Tan,Wan Ni Chia,Xijian Qin,Pei Liu,Mark I.-C. Chen,Charles Tiu,Zhiliang Hu,Vivian Chih-Wei Chen,Barnaby E. Young,Wan Rong Sia,Yee-Joo Tan,Randy Foo,Yongxiang Yi,David C. Lye,Danielle E. Anderson,Lin-Fa Wang

DOI: https://doi.org/10.1038/s41587-020-0631-z

IF: 46.9

2020-07-23

Nature Biotechnology

Abstract:A robust serological test to detect neutralizing antibodies to SARS-CoV-2 is urgently needed to determine not only the infection rate, herd immunity and predicted humoral protection, but also vaccine efficacy during clinical trials and after large-scale vaccination. The current gold standard is the conventional virus neutralization test requiring live pathogen and a biosafety level 3 laboratory. Here, we report a SARS-CoV-2 surrogate virus neutralization test that detects total immunodominant neutralizing antibodies targeting the viral spike (S) protein receptor-binding domain in an isotype- and species-independent manner. Our simple and rapid test is based on antibody-mediated blockage of the interaction between the angiotensin-converting enzyme 2 (ACE2) receptor protein and the receptor-binding domain. The test, which has been validated with two cohorts of patients with COVID-19 in two different countries, achieves 99.93% specificity and 95–100% sensitivity, and differentiates antibody responses to several human coronaviruses. The surrogate virus neutralization test does not require biosafety level 3 containment, making it broadly accessible to the wider community for both research and clinical applications.

biotechnology & applied microbiology
Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

Beomki Lee,Jae-Hoon Ko,Jiho Park,Hee-Won Moon,Jin Yang Baek,Sunhee Jung,Hee-Young Lim,Kyung-Chang Kim,Kyungmin Huh,Sun Young Cho,Cheol-In Kang,Doo Ryeon Chung,Hee Jae Huh,Chi Ryang Chung,Yae-Jean Kim,Eun-Jeong Joo,Eun-Suk Kang,Kyong Ran Peck

DOI: https://doi.org/10.3389/fcimb.2022.822599

IF: 6.073

2022-04-14

Frontiers in Cellular and Infection Microbiology

Abstract:For the clinical application of semi-quantitative anti-SARS-CoV-2 antibody tests, the analytical performance and titer correlation of the plaque reduction neutralization test (PRNT) need to be investigated. We evaluated the analytical performance and PRNT titer-correlation of one surrogate virus neutralization test (sVNT) kit and three chemiluminescent assays. We measured the total antibodies for the receptor-binding domain (RBD) of the spike protein, total antibodies for the nucleocapsid protein (NP), and IgG antibodies for the RBD. All three chemiluminescent assays showed high analytical performance for the detection of SARS-CoV-2 infection, with a sensitivity ≥ 98% and specificity ≥ 99%; those of the sVNT were slightly lower. The representativeness of the neutralizing activity of PRNT ND 50 ≥ 20 was comparable among the four immunoassays (Cohen’s kappa ≈ 0.80). Quantitative titer correlation for high PRNT titers of ND 50 ≥ 50, 200, and 1,000 was investigated with new cut-off values; the anti-RBD IgG antibody kit showed the best performance. It also showed the best linear correlation with PRNT titer in both the acute and convalescent phases (Pearson’s R 0.81 and 0.72, respectively). Due to the slowly waning titer of anti-NP antibodies, the correlation with PRNT titer at the convalescent phase was poor. In conclusion, semi-quantitative immunoassay kits targeting the RBD showed neutralizing activity that was correlated by titer; measurement of anti-NP antibodies would be useful for determining past infections.

immunology,microbiology
Temporal Trend of the SARS-CoV-2 Omicron Variant and RSV in the Nasal Cavity and Accuracy of the Newly Developed Antigen-Detecting Rapid Diagnostic Test

Daisuke Tamura,Yuji Morisawa,Takashi Mato,Shin Nunomiya,Masaki Yoshihiro,Yuta Maehara,Shizuka Ito,Yasushi Ochiai,Hirokazu Yamagishi,Toshihiro Tajima,Takanori Yamagata,Hitoshi Osaka

DOI: https://doi.org/10.3390/diagnostics14010119

IF: 3.6

2024-01-05

Diagnostics

Abstract:The aim of this work is to analyze the viral titers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and respiratory syncytial virus (RSV) at the anterior nasal site (ANS) and nasopharyngeal site (NS), evaluate their virological dynamics, and validate the usefulness of a newly developed two-antigen-detecting rapid antigen diagnostic test (Ag-RDT) that simultaneously detects SARS-CoV-2 and RSV using clinical specimens. This study included 195 asymptomatic to severely ill patients. Overall, 668 specimens were collected simultaneously from the ANS and NS. The cycle threshold (Ct) values calculated from real-time polymerase chain reaction were used to analyze temporal changes in viral load and evaluate the sensitivity and specificity of the Ag-RDT. The mean Ct values for SARS-CoV-2-positive, ANS, and NS specimens were 28.8, 28.9, and 28.7, respectively. The mean Ct values for RSV-positive, ANS, and NS specimens were 28.7, 28.8, and 28.6, respectively. SARS-CoV-2 and RSV showed the same trend in viral load, although the viral load of NS was higher than that of ANS. The sensitivity and specificity of the newly developed Ag-RDT were excellent in specimens collected up to 10 days after the onset of SARS-CoV-2 infection and up to 6 days after the onset of RSV infection.

medicine, general & internal
High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection

Mizuki Fujisawa,Yu Adachi,Taishi Onodera,Nozomi Shiwa-Sudo,Naoko Iwata-Yoshikawa,Noriyo Nagata,Tadaki Suzuki,Shinji Takeoka,Yoshimasa Takahashi

DOI: https://doi.org/10.1016/j.bbrc.2023.06.067

2023-09-17

Abstract:SARS-CoV-2 nucleocapsid protein (NP) is the main target for COVID-19-diagnostic PCR and antigen rapid diagnostic tests (Ag-RDTs). Ag-RDTs are more convenient than PCR tests for point-of-care testing or self-testing to identify the SARS-CoV-2 antigen. The sensitivity and specificity of this method depends mainly on the affinity and specificity of NP-binding antibodies; therefore, antigen-antibody binding is key elements for the Ag-RDTs. Here, we applied the high-throughput antibody isolation platform that has been utilized to isolate therapeutic antibodies against rare epitopes. Two NP antibodies were identified to recognize non-overlapping epitopes with high affinity. One antibody specifically binds to SARS-CoV-2 NP, and the other rapidly and tightly binds to SARS-CoV-2 NP with cross-reactivity to SARS-CoV NP. Furthermore, these antibodies were compatible with a sandwich enzyme-linked immunosorbent assay that exhibited enhanced sensitivity for NP detection compared to the previously isolated NP antibodies. Thus, the NP antibody pair is applicable to more sensitive and specific Ag-RDTs, highlighting the utility of a high-throughput antibody isolation platform for diagnostics development.
A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2–Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation

Zhaohui Cai,Raj Kalkeri,Mingzhu Zhu,Shane Cloney-Clark,Benjamin Haner,Mi Wang,Bahar Osman,Dominic Dent,Sheau-Line Feng,Zach Longacre,Greg Glenn,Joyce S. Plested

DOI: https://doi.org/10.3390/microorganisms12030501

IF: 4.5

2024-02-29

Microorganisms

Abstract:Neutralizing antibody responses from COVID-19 vaccines are pivotal in conferring protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Effective COVID-19 vaccines and assays measuring neutralizing antibodies against emerging variants (i.e., XBB.1.5, XBB.1.16, and XBB.2.3) are needed. The use of biosafety level (BSL)-3 laboratories for live virus assays results in higher costs and a longer turnaround time; therefore, a BSL-2–based pseudovirus neutralization assay (PNT) was developed. The pseudoviruses were produced by cotransfecting cells with plasmids encoding a lentiviral backbone-expressing luciferase reporter; non-surface proteins for lentiviral production; and ancestral or Omicron (BA.1 and BA.5) SARS-CoV-2 spike (S) proteins. The PNT was developed and optimized in dose and kinetics experiments. The representative serum samples (COVID-19–convalescent or NVX-CoV2373–vaccinated participants enrolled in the 2019nCoV-101 trial) demonstrated a wide dynamic range. The neutralization data showed robust correlation with validated anti-recombinant spike IgG levels and angiotensin-converting enzyme 2 inhibition titers (ancestral). This assay is suitable for measurement of the neutralization ability in clinical samples from individuals infected with SARS-CoV-2 or immunized with a COVID-19 vaccine. The results suggest that this PNT provides a lower cost, high-throughput, rapid turnaround alternative to BSL-3–based microneutralization assays and enables the discovery and development of effective vaccines against emerging variants.

microbiology

In-network processing of the GPU-based real-time DXT compression

Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity

Rapid Gel Card Agglutination Assays for Serological Analysis Following SARS-CoV-2 Infection in Humans

A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection

Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen

A Reliable Indirect ELISA Protocol for Detection of Human Antibodies Directed to SARS-CoV-2 NP Protein

An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization

Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2

D313Y mutation in the differential diagnosis of white matter lesions: Experiences from a multiple sclerosis outpatient clinic

Development of a unit conversion tool for five quantitative anti-spike assays and agreement analysis of three qualitative anti-nucleocapsid assays for SARS-CoV-2

Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination

Pre-clinical and clinical evaluation of a surface plasmon field-enhanced fluorescence spectroscopy (SPFS) antigen test for detecting SARS-CoV-2

Nanoparticle-Supported, Rapid, Digital Quantification of Neutralizing Antibodies Against SARS-CoV-2 Variants

Immunomolecular assay based on selective virion capture by spike antibody and viral nucleic acid amplification for detecting intact SARS-CoV-2 particles

Novel enzyme-linked aptamer-antibody sandwich assay and hybrid lateral flow strip for SARS-CoV-2 detection

Clinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS‐CoV‐2 Omicron BA.1 and BA.5 variants

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

Temporal Trend of the SARS-CoV-2 Omicron Variant and RSV in the Nasal Cavity and Accuracy of the Newly Developed Antigen-Detecting Rapid Diagnostic Test

High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection

A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2–Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation